temporal

DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).


These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.

A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.

 

 

Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca and Tesaro. 

Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics. 

Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Pfizer, Roche and Tesaro. 

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro. 

Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca. 

Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Amgen, Novartis, Pfizer and Roche. 

Programme summary
Share this programme
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Lung cancer expert panel Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.